Literature DB >> 2516111

Nonimmunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by nonreducing gel electrophoresis.

D S France1, T E Hughes, R Miserendino, J A Spirito, J Babiak, J B Eskesen, C Tapparelli, J R Paterniti.   

Abstract

A rapid and convenient method for the quantitation of mammalian apoA-I has been developed. The method involves nonreducing sodium dodecyl sulfate gel electrophoresis and Coomassie blue staining, and takes advantage of the relative abundance of apoA-I in whole serum or plasma. ApoA-I was sufficiently resolved to allow quantitation by laser densitometry or spectrophotometry. The assay was linear from 0.25 to 4.0 micrograms of apoA-I. Analytic recovery was 98%. Within-assay variability was 3.1% and between-assay variability was 7.5%. A high degree of positive correlative (r = 0.98) was observed with a human apoA-I radioimmunoassay. For several species investigated, the apoA-I values obtained correlated strongly and positively with high density lipoprotein cholesterol values. When applied to a study of nutritional perturbation in the Mongolian gerbil, the method detected sensible and significant changes in serum apoA-I that paralleled changes in HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516111

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Authors:  S H Zhang; R L Reddick; E Avdievich; L K Surles; R G Jones; J B Reynolds; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

2.  Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia.

Authors:  Marco Busnelli; Stefano Manzini; Alice Colombo; Elsa Franchi; Fabrizia Bonacina; Matteo Chiara; Francesca Arnaboldi; Elena Donetti; Federico Ambrogi; Roberto Oleari; Antonella Lettieri; David Horner; Eugenio Scanziani; Giuseppe Danilo Norata; Giulia Chiesa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-19       Impact factor: 10.514

3.  Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice.

Authors:  G E Homanics; T J Smith; S H Zhang; D Lee; S G Young; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

4.  High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I.

Authors:  M E Swanson; T E Hughes; I S Denny; D S France; J R Paterniti; C Tapparelli; P Gfeller; K Bürki
Journal:  Transgenic Res       Date:  1992-05       Impact factor: 2.788

5.  Decreased capacity to inhibit platelet hyperactivity and to stabilize prostacyclin of high-density lipoproteins in experimental diabetes.

Authors:  I Ginon; C Talussot; G Ponsin; M Ciavatti
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.